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TREM-1 activation is a potential 
key regulator in driving severe 
pathogenesis of enterovirus A71 
infection
Siti Naqiah Amrun1, Jeslin J. L. Tan1, Natasha Y. Rickett2,3, Jonathan A. Cox1,3, Bernett Lee1, 
Michael J. Griffiths3, Tom Solomon2,3,4, David Perera5, Mong How Ooi5,6, Julian A. Hiscox1,2,3* 
& Lisa F. P. Ng1,2,3,7*
Hand, foot and mouth disease (HFMD), caused by enterovirus A71 (EV-A71), presents mild to severe 
disease, and sometimes fatal neurological and respiratory manifestations. However, reasons for the 
severe pathogenesis remain undefined. To investigate this, infection and viral kinetics of EV-A71 
isolates from clinical disease (mild, moderate and severe) from Sarawak, Malaysia, were characterised 
in human rhabdomyosarcoma (RD), neuroblastoma (SH-SY5Y) and peripheral blood mononuclear cells 
(PBMCs). High resolution transcriptomics was used to decipher EV-A71-host interactions in PBMCs. 
Ingenuity analyses revealed similar pathways triggered by all EV-A71 isolates, although the extent 
of activation varied. Importantly, several pathways were found to be specific to the severe isolate, 
including triggering receptor expressed on myeloid cells 1 (TREM-1) signalling. Depletion of TREM-1 in 
EV-A71-infected PBMCs with peptide LP17 resulted in decreased levels of pro-inflammatory genes for 
the moderate and severe isolates. Mechanistically, this is the first report describing the transcriptome 
profiles during EV-A71 infections in primary human cells, and the potential involvement of TREM-1 in 
the severe disease pathogenesis, thus providing new insights for future treatment targets.
Hand, foot and mouth disease (HFMD) is a febrile illness that predominantly affects infants and young chil-
dren, and is characterised by rash and blisters on the hands, mouth, feet and bottoms1–3. Outbreaks of HFMD 
are caused by human enterovirus group A members (HE-A), mainly coxsackieviruses A16, A6 and A10, and 
enterovirus A71 (EV-A71)1,4,5. While often benign and self-limiting2, the disease can cause cardiopulmonary 
and neurological complications such as myocarditis, brainstem encephalitis, aseptic meningitis, and neurogenic 
pulmonary oedema, which can be fatal6,7. The severe manifestations of HFMD are often associated with cases of 
EV-A71 infections, rather than coxsackievirus A168.
EV-A71 belongs to the Enterovirus A species, Enterovirus genus, from the Picornaviridae family9,10. The virus 
has a positive-sense RNA genome of 7.4 kb and encodes for four structural (VP1–4) and seven non-structural 
(2A-C and 3A-D) proteins9. First isolated in California, USA, in 196911, the virus is transmitted via the oral-foecal 
route, saliva and respiratory secretions12. Based on the sequence analysis of VP1 gene, the virus can be broadly 
categorised into six genogroups: A, B, C, D, E and F7,10,13. Whereas genogroup A contains the Californian proto-
type virus BrCr, genogroups B and C consist of various strains, and are further categorised into sub-genogroups 
B0-B5 and C1-C510. B and C genogroups are globally distributed, whereas D, and E and F are limited to India 
and Africa respectively7,10. After the almost total eradication of poliovirus, EV-A71 is now noted as one of the 
most prevalent neurotropic enteroviruses, and is especially endemic in the Asia-Pacific region14–17. Currently, the 
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reasons for the emergence of neurological diseases from EV-A71 infections are still unknown1, and this poses 
a significant public health problem as there are no antivirals available18. Two inactivated EV-A71 vaccines have 
been approved for use by China’s Food and Drug Administration (FDA), but they have not gained widespread 
adoption into immunisation programs globally19,20.
In this study, clinical EV-A71 isolates associated with differing levels of severity (mild, moderate, and severe) 
collected from an outbreak in 2006 in Sarawak, Malaysia21, were used to characterise and compare the infec-
tion kinetics, virus tropism and immuno-pathogenesis using in vitro and ex vivo models. In particular, infection 
kinetics and high-density transcriptomic profiling by RNA-sequencing (RNA-seq) of EV-A71-infected peripheral 
blood mononuclear cells (PBMCs) revealed several virus severity-dependent differences. Collectively, this is the 
first report describing the immune mechanisms involved during EV-A71 infections in primary human cells, and 
the identification of novel pathways, such as triggering receptor expressed on myeloid cells 1 (TREM-1) signal-
ling, that are unique and specific to the severe EV-A71 isolate, and likely contributing to the severe manifestations 
of the disease.
Results
Clinical EV-A71 isolates are phylogenetically classified based on disease outcomes. Six EV-A71 
isolates were identified from patients during an outbreak of HFMD in Sarawak, Malaysia, in 200622. These patients 
had differing levels of disease severity, ranging from mild herpangina/HFMD, severe HFMD in the absence or 
presence of neurological complications, and one fatality (Fig. 1a, Supplementary Fig. S1a). However, alignment 
analysis of the different coding sequences of the virus revealed the isolates to be at least 92% identical to one 
another (Supplementary Table S1). Moreover, phylogenetic classification of the viruses based on the sequence of 
the VP1 gene identified them as belonging to the B5 sub-genogroup, and were closely related to strains circulating 
in Sarawak, Brunei, and Singapore from 2003 to 2008 (Supplementary Fig. S1b). Despite sharing 96% VP1 genetic 
similarity (Supplementary Table S1), all of the isolates, except isolate 3, were observed to be clustered according 
to disease severity in the phylogenetic tree (Supplementary Fig. S1b).
Severe EV-A71 isolate infects human muscle RD cells to high levels. To investigate if the different 
EV-A71 clinical isolates have different infection profiles that could contribute to disease outcome, infection kinet-
ics were compared in human muscle rhabdomyosarcoma (RD) cells and neuroblastoma SH-SY5Y cells at multi-
plicity of infections (MOI) 10 and 1, respectively. These cell lines have been extensively used in elucidating viral 
kinetics7,23 and pathogenesis of enteroviruses24,25. The infection kinetics across a time-course of 0, 3, 6, 12, and 
24 hours post-infection (hpi) were determined by measuring infectivity parameters of percentage of intracellular 
Figure 1. EV-A71 viral isolates from 2006 outbreak in Sarawak, Malaysia, and its viral kinetics in human 
rhabdomyosarcoma (RD) and neuroblastoma (SH-SY5Y) cells. (a) Clinical information about the viruses 
isolated including genotype, symptoms and area virus was isolated from. (b–e) RD and SH-SY5Y cells were 
infected with mild, moderate and severe isolates of EV-A71 at MOI 10 and 1 respectively, and harvested at 
0, 3, 6, 12 and 24 hours post-infection (hpi). (b,c) Infection kinetics in RD cells via (b) quantification of VP1 
antigen by flow cytometry and (c) viral load quantification of VP1 RNA by qRT-PCR. (d,e) Infection kinetics in 
SH-SY5Y cells via (d) quantification of VP1 antigen by flow cytometry and (e) viral load quantification of VP1 
RNA by qRT-PCR. Data are presented as mean ± SEM and representative of three independent experiments. 
Statistical analysis was carried out with Kruskal-Wallis with Dunn’s multiple comparisons test to compare 
among EV-A71 isolates at the respective time-points (**p<0.01; ***p<0.001) [Mild vs Severe EV-A71 (*); 
Moderate vs Severe EV-A71 (+)].
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VP1 antigen-positive cells by flow cytometry (Supplementary Fig. S2a) and levels of VP1 RNA load by qRT-PCR. 
In RD cells, the percentage of infected VP1+ cells among the EV-A71 isolates 1, 2 and 3 within the mild disease 
phenotype group were similar by 24 hpi (Supplementary Fig. S2b). Likewise, there were no significant differences 
between isolates 5 and 6 of the severe phenotype over the course of the time-points (Supplementary Fig. S2c). As 
such, isolates 1, 4 and 5 were chosen as representatives for further characterisation, and were defined as “mild”, 
“moderate”, and “severe” EV-A71 isolates respectively.
The severe isolate showed the highest level of infection in RD cells, followed by moderate and mild (Fig. 1b,c). 
The percentage of EV-A71 VP1 antigen in live cells assessed via flow cytometry showed that by 24 hpi, severe 
EV-A71-infected RD cells exhibited the highest levels of VP1+ cells, followed closely by moderate EV-A71, and 
mild EV-A71 (Fig. 1b). Severe EV-A71 also showed significantly higher virus replication compared to the mild 
isolate from 3 to 24 hpi, whereas moderate EV-A71 had higher VP1 RNA copies than mild EV-A71 only at 24 hpi 
(Fig. 1c). However, there were no significant differences in percentage of VP1+ cells and viral RNA copies among 
the three isolates at almost all time-points in SH-SY5Y cells (Fig. 1d,e).
Primary human monocytes, B and T cells are the main targets of EV-A71. Infection kinetics of 
the different EV-A71 isolates were next explored in human PBMCs to assess if the associated disease severity 
affects the ability of the virus to infect the primary cells, which are more biologically relevant than cell lines. In 
this ex vivo model, healthy donor PBMCs were infected with mild, moderate, severe, and heat-inactivated forms 
of EV-A71 at MOI 5 over 0, 6, 12 and 24 hpi. PBMCs infected with moderate and severe isolates of EV-A71 had 
higher levels of viral VP1 RNA load compared to the mild isolate (Fig. 2a). The latter showed lower and limited 
viral replication throughout the course of infection, whereas moderate EV-A71-infected PBMCs had the highest 
viral load in the initial phase, before steadily decreasing over time (Fig. 2a). However, PBMCs infected with the 
severe isolate demonstrated increasing viral load levels till 12 hpi, before dropping off at 24 hpi (Fig. 2a). These 
observed trends were also consistent with the percentage of EV-A71 VP1 antigen detected from total CD45+ 
leucocytes (Fig. 2b,c).
To identify the specific subsets susceptible to EV-A71 infection, cells were further gated into the different 
populations: T cells, B cells, monocytes, and natural killer (NK) cells (Supplementary Fig. S2d). T and B lym-
phocytes, as well as monocytes, were the main susceptible subsets within the PBMCs (Fig. 2b,c). In contrast, NK 
cells showed limited and lower levels of infectivity (Supplementary Fig. S2e). Again, PBMCs infected with mild 
EV-A71 demonstrated an overall limited percentage of VP1 antigen within the three susceptible subsets (Fig. 2b), 
whereas moderate-infected PBMCs showed highest VP1 percentage in B cells, followed closely by monocytes, and 
T cells (Fig. 2b). On the other hand, PBMCs infected with the severe isolate displayed a slightly different trend, 
with the highest percentage of VP1 antigen observed in the monocytes, followed by B cells and T cells (Fig. 2b). 
Figure 2. EV-A71 infection in primary human peripheral blood mononuclear cells (PBMCs). Human primary 
PBMCs (n = 5–9) were infected with mild, moderate, severe and heat-inactivated EV-A71 isolates at MOI 5, 
and harvested at 0, 6, 12 and 24 hpi for viral load quantification and flow cytometry. (a) Viral load levels were 
determined by qRT-PCR. (b,c) Percentage of EV-A71 Ag+ cells from total CD45+, CD3+ T cells, CD19+ B 
cells and CD14+ monocytes were determined via flow cytometry. (b) Bar graphs showing the levels of EV-A71 
Ag+ cells from the different cell subsets. Data are presented as mean ± SEM. (c) Illustration of representative 
contour plots from one donor at 12 hpi. Statistical analysis was carried out with Kruskal-Wallis with Dunn’s 
multiple comparisons test to compare among EV-A71 isolates at the respective time-points (*p < 0.05; 
**p < 0.01; ***p < 0.001).
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Moreover, there was an increase in the percentage of VP1 antigen in the B and T lymphocytes populations at 6 hpi 
and 12 hpi respectively, whereas in the monocytes the percentage decreased at 6 hpi but was sustained throughout 
the course of infection (Fig. 2b).
Transcriptomic profiling reveals a strong induction of host antiviral immune response upon 
EV-A71 infection. To identify the possible mediators responsible for the disease severity-dependent differ-
ences, RNA-seq was performed on samples of EV-A71-infected PBMCs from four donors to identify and quan-
titate mRNA abundance and changes throughout the course of infection at 0, 6, 12 and 24 hpi. Mapped genes of 
infected conditions were normalised to a heat-inactivated control virus at the respective time-points. The results 
showed that the number of significant differentially expressed transcripts (false discovery rate [FDR] < 0.05) 
were different across time-points as well as isolates (Fig. 3a). During the course of infection, the greatest change 
occurred from 0 to 6 hpi for all EV-A71 isolates, as indicated by the sharp increase in the number of differentially 
expressed genes (DEGs), and the amount of DEGs continued to show an overall increasing trend from 6 to 24 hpi 
(Fig. 3a). Moderate EV-A71 demonstrated the highest numbers of DEGs throughout infection, followed by severe 
EV-A71, and mild EV-A71 (Fig. 3a).
Significant DEGs of the respective isolates and time-points were analysed in Ingenuity Pathway Analysis 
(IPA) to identify functional pathways (Fig. 3b). The numbers of significantly enriched canonical pathways 
[-log(p-value) > 1.30] were highest for severe EV-A71-infected PBMCs, especially from 6 to 24 hpi (Fig. 3b), 
despite being presented with fewer differentially expressed transcripts than moderate-infected PBMCs (Fig. 3a). 
PBMCs infected with mild EV-A71 displayed the lowest number of functional pathways (Fig. 3b).
In order to characterise the cellular responses elicited upon EV-A71 infection, transcripts that were common 
among the three isolates at time-points 6 to 24 hpi were identified and further analysed. Regardless of isolate 
severity, a total of 36 genes were differentially expressed during EV-A71 infection (Supplementary Table S2), 
and these genes are known to be involved in the antiviral interferon response, inflammatory processes, as well as 
in apoptosis (Fig. 3c). Nonetheless, the proportion of fold change for most of the genes differed across time and 
among the EV-A71 isolates. Notably, PBMCs infected with moderate EV-A71 showed a stronger response than 
the mild and severe isolates, specifically interferon-stimulated gene 15 (ISG15), viperin (RSAD2), ubiquitin spe-
cific peptidase 18 (USP18), interferon alpha inducible protein 27 (IFI27), and guanosine monophosphate reduc-
tase (GMPR) (Fig. 3c). Next, in order to identify the common functional pathways, the 36 genes were further 
analysed in IPA. The results yielded 12 significant canonical pathways (Supplementary Table S3) and expectedly, 
the antiviral response and virus recognition formed the top four pathways (Fig. 3d,e). Based on the activation 
z-scores generated by IPA, the interferon and RIG-I like signalling pathways were equally activated among the 
EV-A71 isolates, and across time (Fig. 3e). The pathway involving virus recognition by pattern recognition recep-
tors (PRR) was most significantly activated in severe EV-A71-infected conditions at 6 hpi that persisted till 24 
hpi (Fig. 3e). However, a different pattern was observed for mild and moderate EV-A71 infections, in which the 
activation of this pathway became less pronounced over time (Fig. 3e). Similar observations were also seen for the 
interferon-regulatory factor (IRF) activation pathway (Fig. 3e).
Activation of TREM-1 pathway is specific to severe EV-A71 infection. Given that the different 
EV-A71 isolates belonged to the same sub-genotype B5 (Supplementary Fig. S1b), and yet were able to give rise 
to such varied clinical outcomes in patients (Fig. 1a), we then sought to understand this by identifying and com-
paring the unique DEGs of the EV-A71 isolates at the respective time-points of 6, 12 and 24 hpi. The three 
isolates showed distinctive trends (Fig. 4a). While the number of unique genes increased slightly from 6 to 13 
DEGs (6 to 24 hpi) in the mild-infected condition, the moderate EV-A71-infected PBMCs displayed an opposite 
trend, with a decrease in the numbers from 42 to 20 DEGs (Fig. 4a). On the other hand, infection of PBMCs 
with severe EV-A71 isolate showed an increasing number of DEGs specific to this isolate (4 to 16 DEGs at 6 and 
24 hpi) (Fig. 4a). Examples of enriched DEGs distinct to each isolate were nuclear protein 1 (NUPR1) for mild, 
chemokine (C-X-C motif) ligand 13 (CXCL13) for moderate, and interleukin-6 (IL-6) for severe EV-A71 infec-
tions (Supplementary Table S4). An analysis of the unique DEGs with IPA revealed significant canonical pathways 
similar to the observations as in Fig. 4a (Fig. 4b).
Since the numbers of activated canonical pathways in EV-A71-infected PBMCs were the highest at 24 hpi 
(Figs. 3b and 4b), the differential genes of each isolate at this particular time-point were input into IPA and 
comparison analyses were carried out (Supplementary Table S4). The top 10 canonical pathways, based on the 
activation z-scores as determined by IPA, were selected for further analysis (Fig. 4c and Supplementary Table S5). 
Remarkably, PBMCs infected with severe EV-A71 showed a very distinctive response. Pathways such as IL-6, 
neuroinflammation, role of IL-17F in allergic inflammatory airway diseases, and TREM-1 signalling processes 
were significantly and highly activated but were absent or lacking in the mild and moderate EV-A71-infected 
conditions (Fig. 4c). Notably, the TREM-1 signalling pathway was most distinctive in severe EV-A71 infection 
(Fig. 4c). The expression of genes involved in this pathway were strongly enriched for CXCL3, IL-1β and IL-6 in 
the severe-infected condition (Fig. 4d). Moreover, TREM-1 pathway had not been explored before in the context 
of EV-A71 infection, and as such, this pathway was further studied in subsequent experiments.
Reduced TREM-1 expression mitigates EV-A71 infection. To verify the role of TREM-1 signal-
ling pathway as an important mediator in EV-A71 infection, a series of blocking experiments were carried out 
in which healthy donor PBMCs were pre-treated with 100 ng/ml of synthetic peptide LP17 (Supplementary 
Fig. S3a). LP17 was previously shown to be able to compete with the ligand and block the TREM-1 receptor, thus 
inhibiting inflammatory responses26–28. A scrambled form of the peptide, named sLP17, was used as negative 
control (Supplementary Fig. S3a). PBMCs were then infected with mild, moderate and severe EV-A71 isolates at 
MOI 5, as well as mock-infected, before fresh media containing the final concentration of peptides were added 
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Figure 3. Transcriptomic profiling of human PBMCs during EV-A71 infection. Primary human PBMCs (n = 4) 
were infected with mild, moderate, severe and heat-inactivated EV-A71 isolates at MOI 5, and harvested at 0, 
6, 12 and 24 hpi for transcriptomic analysis by RNA-seq. Results of infected conditions were compared to heat-
inactivated control, and the log2-(fold change) values were analysed in Ingenuity Pathway Analysis (IPA). (a,b) 
Overall changes of significant (a) differentially expressed genes (DEGs) and (b) canonical pathways identified 
by IPA over time and in different isolates. (c) Heat-map showing normalised log2-(fold change) values of the 
common DEGs in all infected conditions of 6, 12 and 24 hpi. (d) Significant canonical pathways determined 
by IPA from the common DEGs in  (c) (*p < 0.05; ***p < 0.001). (e) Heat-map showing the activation z-score 
values of the top four canonical pathways as determined by IPA.
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(Supplementary Fig. S3a). In addition, as positive controls, PBMCs were subjected to lipopolysaccharide (LPS) 
treatment in the presence of peptides. To validate that the blocking was efficient, total RNA samples of peptide- 
and LPS-treated PBMCs were subjected to gene expression studies by qRT-PCR (Supplementary Fig. S3b). LPS 
controls with LP17 peptide treatment resulted in decreased expression levels of the genes of interest, especially 
IL-6 and CCL7, indicating a successful TREM-1 inhibition (Supplementary Fig. S3b).
Similarly, in the EV-A71-infected conditions, a reduced gene expression profile was observed for the mod-
erate and severe EV-A71 isolates (Fig. 5a). However, the intensity of TREM-1 inhibition was more pronounced 
Figure 4. Differences in transcriptomic profiles of human PBMCs infected with different EV-A71 isolates. 
Primary human PBMCs (n = 4) were infected with mild, moderate, severe and heat-inactivated EV-A71 isolates 
at MOI 5, and harvested at 0, 6, 12 and 24 hpi for transcriptomic analysis by RNA-seq. Results of infected 
conditions were compared to heat-inactivated control, and the log2-(fold change) values were analysed in 
Ingenuity Pathway Analysis (IPA). (a,b) Venn diagrams illustrating the number of significant (a) differentially 
expressed genes (DEGs) and (b) canonical pathways of the different EV-A71 isolates at 6, 12 and 24 hpi. (c) 
Heat-map showing the activation z-scores of the top 10 canonical pathways at 24 hpi as determined by IPA. 
Asterisks indicate the significance of the pathway in respective isolates. (d) Heat-map showing normalised 
log2-(fold change) values of the genes involved in TREM-1 signalling pathway at 24 hpi. Grey boxes indicate no 
values. (*p < 0.05; **p < 0.01; ***p < 0.001).
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in moderate isolate infection when compared to severe-infected condition (Fig. 5a). On the other hand, mild 
EV-A71 showed minimal changes in the relative level of gene expression, suggesting that TREM-1 activation 
in this isolate could be too low to detect for any inhibition (Fig. 5a). The impact of EV-A71 viral replication 
upon TREM-1 inhibition was then assessed by qRT-PCR. Consistent with the minor effects observed in the gene 
expression results, infection with mild EV-A71 showed no differences in the number of viral VP1 RNA copies 
under the blocked and control states (Fig. 5b). However, despite changes in the gene expression profile, the treat-
ment with LP17 to inhibit TREM-1 had no significant effect on viral VP1 RNA load in both the moderate and 
severe EV-A71 infections (Fig. 5b).
Figure 5. Blocking of TREM-1 by peptide LP17 decreased the expression levels of pro-inflammatory genes 
during moderate and severe EV-A71 infection. Human primary PBMCs (n = 7) were pre-treated with 100 ng/
ml of LP17 or the control sLP17 peptide, before infection with mild, moderate, or severe EV71 isolates at MOI 
5. Mock-infected PBMCs were used as negative control. Cells were replenished with fresh media containing 
respective peptides and harvested at 24 hpi for gene expression and viral load quantifications. (a) Total RNA 
samples were extracted and gene expression studies were performed via qRT-PCR using 10 ng/µl of RNA. 
Relative expression levels of genes were calculated by comparing the infected conditions to the respective mock. 
Bar graphs illustrating the expression levels of genes involved in the TREM-1 pathway. Dotted line indicates 
the baseline levels from mock. (b) Viral load levels were quantified by qRT-PCR of the VP1 RNA copies. Data 
are presented as mean ± SD. Statistical analysis was carried out with Wilcoxon matched-pairs signed rank test 
(*p < 0.05).
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Discussion
Patients suffering from EV-A71 infections can present different clinical manifestations and severity. Previous stud-
ies have suggested that outcomes of EV-A71 infections could be influenced by the genetic makeup of the virus, 
as well as the immune status of the patient21,29–32. The amino acid residue at position 145 of VP1 protein varies 
among EV-A71 isolates, comprising of either glycine (G), glutamine (Q) or glutamic acid (E)33. Variability at this 
position is critical as it determines the attachment of the virus to the cell surface, thus influencing its virulence33,34. 
Reports have shown that isolates which have G or Q residues are isolated more frequently from patients with 
severe EV-A71 infections33,35–38. Indeed, the moderate and severe EV-A71 isolates in this study possess the Q and 
G residues respectively, while the mild isolate has the E residue at this position (Supplementary Fig. S4a). In addi-
tion, nucleotide alignment of the various genes of the isolates revealed that non-structural gene 3A was dissimilar 
between the isolates (92% identity) (Supplementary Table S1). The 3A protein has been shown to be important for 
virus RNA replication, with its involvement in the formation of replication organelles39–41. It was recently reported 
that recruitment of phosphatidylinositol 4-kinase IIIβ (PI4KB) by the interaction of host factor acyl-CoA binding 
domain containing 3 (ACBD3) and EV-A71 3A facilitated viral replication42. Sequence alignment of the 3A protein 
reveals only one amino acid difference at position 61 (Supplementary Fig. S4b) in which the mild isolate has an 
isoleucine (I) residue whereas the moderate and severe isolates have valine (V) instead. Despite these differences, 
all EV-A71 isolates were highly genetically identical overall (at least 96%). Yet, viral severity-dependent effects were 
observed in muscle RD cells and in PBMCs. Moderate and severe EV-A71 isolates demonstrated high levels of 
infection and replication, while mild EV-A71 showed lower infectivity. However, in neuronal SH-SY5Y cells, mild 
and moderate EV-A71 exhibited similar levels of replication kinetics as the severe isolate, suggesting that EV-A71 
replication is cell-type dependent43 and that the mild and moderate isolates could potentially cause neuropatho-
genesis if the blood-brain barrier permeability is compromised. Therefore, the results support the importance of the 
virus’ genetic component in determining virulence and in shaping clinical outcomes in patients.
Intriguingly, between the moderate and severe EV-A71 infections in PBMCs, the latter exhibited a steady 
increase in infection and replication over time while the former showed a strong infection only in the initial 
phase. This was also supported in the transcriptomic results, in which the viral recognition pathway by PRR 
remained activated specifically for severe EV-A71, thus emphasising the ongoing replication of virus over time. 
In addition, several pathways such as neuroinflammation and IL-6 signalling were identified to be strongly asso-
ciated or unique to severe EV-A71 infection. Cytokines IL-1β and IL-6 are the common denominators of these 
pathways and are therefore likely to play a role in the severe pathogenesis of EV-A71. In earlier reports, levels 
of IL-1β, IL-6 and TNFα were found to be significantly elevated in fatal EV-A71 patients with encephalitis and 
pulmonary oedema, when compared to patients with no complications31,44–46. Production of such inflamma-
tory cytokines are mediated by monocytes, macrophages, as well as T and B lymphocytes46. Furthermore, these 
immune cells were the subsets shown to be the most susceptible to EV-A71 in this study and elsewhere47–49.
The link between pro-inflammatory response and severe EV-A71 outcome is also further strengthened with the 
identification of TREM-1 activation, which is unique and distinct to the severe isolate. TREM-1 is a cell surface recep-
tor that is highly expressed on monocytes and neutrophils, and is known as a critical player in the amplification of 
inflammation via the production of pro-inflammatory mediators50. TREM-1 can also exist as a soluble variant, with 
its expression levels indirectly proportional to that of its receptor form50. To date, TREM-1 modulation in viral infec-
tions has been described for dengue, Marburg (MARV), Ebola (EBOV) and human immunodeficiency (HIV) viruses 
among others28,51,52. In dengue-infected patients, the expression of TREM-1 on neutrophils was significantly reduced 
in the acute phase of the disease, with high levels of soluble TREM-1 in sera51. On the other hand, HIV upregulated 
TREM-1 expression on human macrophages, preventing its apoptosis and mediating infection52. In addition, MARV 
and EBOV were able to activate TREM-1 on human neutrophils in vitro, and the blocking of TREM-1 receptor by 
LP17 peptide treatment resulted in diminished production of TNFα and IL-1β28. Although a decrease in the expres-
sion of pro-inflammatory mediators was also observed in this study, the effect of the treatment was most significant for 
the moderate isolate of EV-A71. Moreover, although a lower viral load was observed in the blocked conditions of mod-
erate and severe infections, results were not significant when compared to the control condition. Therefore, inhibition 
of TREM-1 specifically targeted the downstream immune response after virus infection (Fig. 5). Previously, TREM-
1-deficient mice infected with either Leishmania major, influenza virus or Legionella pneumophila were able to demon-
strate reduced morbidity and immune-associated pathologies, with minimal effect on pathogen clearance53. Another 
plausible explanation could be attributed to the host genetic factors, as donor-to-donor variations were observed in our 
study. Gene polymorphisms within TREM-1 have been linked to the development of inflammation and sepsis54, and it 
has been reported that there is a positive association between patients carrying the TREM-1 rs2234237T allele and the 
development of severe malaria, due to the presence of higher levels of soluble TREM-1 in the plasma of these patients55. 
Given that polymorphisms in EV-A71 receptors, scavenger receptor class B member 2 (SCARB2) and P-selectin gly-
coprotein ligand-1 (PSGL-1), have been shown to affect EV-A71 susceptibility and infection respectively56, genomic 
variations within TREM-1 could also play a probable role in modulating EV-A71 infection and outcomes. Therefore, 
further investigations in patients are required to support and validate the findings of this study.
In conclusion, this study characterised and compared the cellular responses elicited by EV-A71 isolates of 
differing clinical severity and revealed the potential novel involvement of TREM-1 in the pathogenesis of severe 
EV-A71 infection. Importantly, TREM-1 expression levels could serve as a prognostic marker for severe EV-A71 
infections in patients, and might point the way towards future therapies.
Methods
Ethics approval. Human blood and apheresis cone bloods were obtained from healthy volunteers with writ-
ten informed consent, in accordance with the Declaration of Helsinki for Human Research, and with guidelines 
from the Health Sciences Authority of Singapore. Study protocols were approved by the SingHealth Centralised 
Institutional Review Board (CIRB reference numbers: 2017/2806 and 2017/2512).
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Cells and viruses. Human rhabdomyosarcoma (RD; ATCC CCL-136) and neuroblastoma (SH-SY5Y; 
ATCC CRL-2266) cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) and Roswell Park 
Memorial Institute (RPMI) (GE Healthcare Life Sciences) respectively, supplemented with 10% foetal bovine 
serum (FBS; GE Healthcare Life Sciences) at 37 °C with 5% CO2. EV-A71 viral isolates used in this study were 
originally isolated from six patients from the 2006 outbreak in Sarawak, Malaysia (sequence data submitted to the 
GenBank databases under accession numbers MN053430, MN053431, MN053432, MN053433, MN053434 and 
MN053435). Viruses were propagated for three passages and titred in RD cells, and stored at −80 °C. The same 
passage number of viruses were used for infection experiments. Heat-inactivation of virus was done at 65 °C for 
45 min.
Tissue culture infective dose 50 (TCID50) assay. Viral titers were determined in RD cells via TCID50 
assay. Briefly, RD cells (1.5 × 104) were seeded in 96-well microtiter plates overnight before infection with serial 
dilutions of EV-A71 isolates in serum-free DMEM. After 1.5 h, cells were refreshed with DMEM with 10% FBS 
and incubated for 4 days at 37 °C. Cells were fixed with 10% formalin (Sigma-Aldrich) before being stained with 
0.5% crystal violet (Sigma-Aldrich). Titre was calculated using Reed-Muench method57.
Genome sequencing and phylogenetic analysis. Viral RNA of the EV-A71 isolates was extracted 
using QIAamp Viral RNA Mini Kit (Qiagen) as per manufacturer’s instructions. 30 ng of viral RNA samples were 
subjected to cDNA synthesis using Illumina TruSeq RNA sample preparation kit version 2 (Low-Throughput 
protocol) according to manufacturer’s protocol, except for the following modifications: 1. Skip mRNA purifica-
tion and start with RNA fragmentation 2. use of 12 PCR cycles, 3. two additional round of Agencourt Ampure 
XP SPRI beads (Beckman Coulter) to remove >600 bp double stranded cDNA. The length distribution of the 
cDNA libraries was monitored using DNA 1000 kits on the Agilent bioanalyser. All samples were subjected to an 
indexed SE sequencing run of 1 × 51 cycles on an Illumina MiSeq (18 samples/lane). EV-A71 sub-genogroup B 
phylogenetic tree was generated by maximum-likelihood analysis of complete VP1 nucleotide sequences aligned 
using MUSCLE in MEGA. The tree was rooted to the prototype genogroup A strain. Sequences were identified by 
GenBank accession, year of isolation, and country of origin. Tree robustness was evaluated by bootstrap analysis 
using 1000 pseudo-replicate sequences. Major clades of bootstrap values of more than 75% were indicated at 
relevant branch nodes.
In vitro infection of cell lines. RD and SH-SY5Y cells (1 × 106) seeded in 60 mm dish were infected with 
the EV-A71 isolates prepared in serum-free media at multiplicity of infection (MOI) 10 and 1, respectively25,58–61. 
After 1.5 h, virus inoculum was removed and replaced with media containing 10% FBS. Cells were incubated at 
37 °C and harvested at time-points 0, 3, 6, 12, and 24 hours post-infection (hpi). Mock-infected controls were cells 
without any virus infection.
Ex vivo treatment and infection of human peripheral blood mononuclear cells (PBMCs). PBMCs 
were first isolated from a blood apheresis cone by gradient centrifugation using Ficoll-Hypaque method as pre-
viously described62,63. PBMCs (2 × 106) were then infected with EV-A71 viral isolates at MOI 5 in serum-free 
Iscove’s Modified Dulbecco’s Medium (IMDM; Gibco)60. After 2 h, virus inoculum was removed and replaced 
with IMDM with 10% human serum (HS; Innovative Research Inc). Cells were incubated at 37 °C and har-
vested at time-points 0, 6, 12, and 24 hpi. Mock-infected controls were cells without any virus infection, whereas 
heat-inactivated controls were cells infected with heat-inactivated virus. For TREM-1 blocking experiments, iso-
lated PBMCs were first pre-treated with 100 ng/ml of LP17 peptide (LQVTDSGLYRCVIYHPP) or its scrambled 
form, sLP17 (TDSRCVIGLYHPPLQVY) (Pepscan Systems) as previously described26,27, in serum-free IMDM. 
After 30 min incubation at 37 °C, PBMCs were then infected with EV-A71. Subsequently, peptide-virus solu-
tions were removed and cells were refreshed with 100 ng/ml of sLP17 or LP17 peptides in IMDM and 10% HS. 
Mock-infected, and LPS-treated PBMCs (50 ng/ml; Sigma-Aldrich) were used as negative and positive controls, 
respectively.
Viral RNA extraction and viral RNA quantification. Viral RNA from 140 μl of culture supernatant 
was extracted using QIAamp Viral RNA Mini Kit (Qiagen) according to manufacturer’s instructions. Viral load 
quantification was performed with a VP1-targeted quantitative real-time polymerase chain reaction (qRT-PCR) 
adapted from Tan and colleagues64, with forward and reverse primers (GAGAGCTCTATAGGAGACAGT and 
GAGAGCTCTATAGGAGACAGT respectively), and an additional novel lab-designed FAM-labeled molecular 
beacon probe (ACCCACAGGTCAAAACACACA) taken from consensus sequence of the six EV-A71 isolates. 
RT-PCR reactions were prepared using QuantiTect Probe RT-PCR Kit (Qiagen), with final concentrations of 
primers and probe used were 400 nM and 200 nM respectively. The thermal cycling conditions were: 50 °C for 
30 min, 95 °C for 15 min, followed by a 2-step cycle of a cycle at 94 °C for 15 min, and 45 cycles at 55 °C for 1 min 
on 7900HT Fast Real-Time PCR System (Applied Biosystems). Assay exclusivity of EV-A71-VP1 was confirmed 
by testing viral RNA extracted from dengue viruses (DENV-1 to DENV-4), Chikungunya virus (CHIKV), and 
O’nyong’nyong virus (ONNV). Analytical sensitivity was also determined using quantitated EV-A71 RNA tran-
scripts. The lower limit of detection was estimated as 10 copies for the VP1 gene target. Copy numbers of EV-A71 
RNA were determined using the Ribogreen RNA-specific Quantitation Kit (Invitrogen). RNA transcripts from 
10 to 109 copies were performed in pentaplicates to construct a standard curve to estimate EV-A71 copy number 
in samples.
Flow cytometry. RD and SH-SY5Y cells from in vitro infections were stained with LIVE/DEAD 
Fixable Aqua Dead Stain (Life Technologies), fixed with 1X BD FACS Lysing Solution (BD Biosciences), and 
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permeabilised with 1X BD FACS Permeabilising Solution 2 (BD Biosciences). Subsequently, cells were stained 
with EV-A71 VP1 protein specific mouse monoclonal antibody (clone 10F0; Abcam), and counter-stained with 
fluorophore-tagged goat anti-mouse IgG (H + L) antibody (Thermo Fisher Scientific), before being acquired with 
BD FACSCanto II (BD Biosciences). PBMCs from ex vivo infections were stained and fixed similarly as above, 
and permeabilised with 0.5% Triton X-100 (Sigma-Aldrich). Cell surface staining was performed with mouse 
anti-human CD45 (clone HI30; BioLegend), CD3 (clone SP34-2; BD Biosciences), CD19 (clone SJ25C1; eBiosci-
ence), CD14 (clone M5E2; BD Pharmingen), CD16 (clone 3G8; BioLegend), CD56 (clone AF12-7H3; Miltenyi 
Biotec), CD11c (clone 3.9; BioLegend), HLA-DR (clone L243; BioLegend), followed by EV-A71 VP1 staining and 
its counter-stain, as above. Cells were acquired with BD LSRFortessa (BD Biosciences). Flow cytometry data were 
analysed with FlowJo version 9.3.2 (Tree Star, Inc).
Total RNA extraction. Total RNA from cells of PBMCs infections were extracted using RNeasy Micro Kit 
(Qiagen) according to manufacturer’s instructions, and the concentrations quantified with Nanodrop 1000 spec-
trophotometer (Thermo Fisher Scientific).
Gene expression. Total RNA samples were diluted to a concentration of 10 ng/μl prior to gene expres-
sion studies by qRT-PCR using QuantiFast SYBR green RT-PCR kit (Qiagen) in 7900HT Fast Real-Time PCR 
System (Applied Biosystems)65,66 according to manufacturer’s protocol. The Ct values for CXCL3, IL-1β, IL-6, 
CCL2, CCL7, CCL3, TLR7, TNFα and GAPDH (housekeeping gene) were determined. The fold change relative 
to mock-infected samples for each gene was determined using the ΔCt method and Microsoft Excel 201665,66. The 
sequences of the primers used are in Supplementary Table S6.
RNA-seq and differential gene expression analysis. The methods for RNA-seq and differential expres-
sion were previously described67–69 and are briefly described below.
RNA-seq. RNA-seq was performed as previously described67–69. Briefly, RNA samples were DNase-treated 
using Ambion Turbo DNA-free Kit (Invitrogen), purified using Agencourt Ampure XP beads (Beckman Coulter), 
followed by a Ribozero treatment using the Epicentre Ribo-Zero Gold Kit (Human/Rat/Mouse) (Ilumina), and 
purified again with Ampure XP beads. Successful depletion was then quality tested using Qubit 4 Fluorometer 
(Thermo Fisher) and Agilent 2100 Bioanalyser (Agilent Technologies), and all of the depleted RNA was used as 
input material for the ScriptSeq v2 RNA-Seq Library Preparation protocol. Following 14 cycles of amplification, 
the libraries were purified using Ampure XP beads. Each library was quantified using Qubit, and the size distri-
bution was assessed using the AATI Fragment Analyser (Advanced Analytical). Final libraries were pooled in 
equimolar amounts, and the quantity and quality of each pool was assessed by the Fragment Analyser and sub-
sequently by qPCR using the Illumina Library Quantification Kit (Kapa Biosystems) on a Light Cycler LC480II 
(Roche) according to manufacturer’s instructions. The template DNA was denatured according to the protocol 
described in the Illumina cBot User guide and loaded at 12 pM concentration. To improve sequencing quality 
control 1% PhiX was spiked-in. Sequencing was carried out on three lanes of an Illumina HiSeq. 2500 with ver-
sion 4 chemistry, generating 2 × 125 bp paired-end reads.
Bioinformatics analysis. Briefly, base calling and de-multiplexing of indexed reads were performed by 
CASAVA version 1.8.2 (Illumina) to produce 30 samples from the 5 lanes of sequence data, in fastq format. The 
raw fastq files were trimmed to remove Illumina adapter sequences using Cutadapt version 1.2.170. The option 
“-O 3” was set, so that the 3′ end of any reads which matched the adapter sequence over at least 3 bp was removed. 
The reads were further trimmed to remove low quality bases, using Sickle version 1.200 with a minimum window 
quality score of 20. After trimming, reads shorter than 50 bp were removed. If both reads from a pair passed this 
filter, each was included in the R1 (forward reads) or R2 (reverse reads) file. If only one of a read pair passed this 
filter, it was included in the R0 (unpaired reads) file. The reference genome used for alignment was the human ref-
erence genome assembly GRCh38. The reference annotation was downloaded from the Ensembl ftp site (ftp://ftp.
ensembl.org/pub/release-77/gtf/homo_sapiens/Homo_sapiens.GRCh38.77.gtf.gz). The annotated file contained 
63,152 genes. R1/R2 read pairs were mapped to the reference sequence using TopHat2 version 2.1.071 which calls 
the mapper Bowtie2 version 2.0.1072. Data are accessible at NCBI’s Gene Expression Omnibus (GEO) database 
(accession number GSE135964).
Differential gene expression and functional analysis. Mapped reads were further analysed using edgeR 
version 3.373 to calculate normalised counts per million (CPM), to identify genes differentially expressed between 
infected and heat-inactivated conditions. The log2-(fold change) values of such genes were uploaded into Ingenuity 
Pathway Analysis (IPA; Qiagen) and subsequently used for gene ontology and pathway analysis. IPA was performed 
to identify canonical pathways, and comparison analysis was used to determine the most significant pathways 
across the different isolates and time-points. Activation z-scores and p-values associated with the identified func-
tional pathways were determined by IPA. Heat-maps were generated using TM4 Multi-Experiment Viewer74.
Statistical analysis. All statistical analyses were performed using GraphPad Prism 7 (GraphPad Software). 
For cell lines and PBMCs infection experiments, Kruskal-Wallis with Dunn’s multiple comparison test was used 
to compare the EV-A71 isolates at each time-point. For peptide-PBMCs experiments, Wilcoxon matched-pairs 
signed rank test was used in the comparison of LP17 and control sLP17 peptides in the respective infected condi-
tion. P values less than 0.05 are considered to be statistically significant.
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